檢索結果 - Deborah Collyar

  • Showing 1 - 17 results of 17
Refine Results
  1. 1
    The Challenge for Development of Valuable Immuno-oncology Biomarkers

    The Challenge for Development of Valuable Immuno-oncology Biomarkers 由 Janice M. Mehnert, Arta M. Monjazeb, Johanna M.T. Beerthuijzen, Deborah Collyar, Larry Rubinstein, Lyndsay N. Harris

    出版 2017
    獲取全文 獲取全文
    Editorial
    加到收藏夾
    Saved in:
  2. 2
    Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity

    Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity 由 Valsamo Anagnostou, Mark Yarchoan, Aaron R. Hansen, Hao Wang, Franco Verde, Elad Sharon, Deborah Collyar, Laura Q.M. Chow, Patrick M. Forde

    出版 2017
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  3. 3
    Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities

    Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities 由 Christina S. Baik, Eric H. Rubin, Patrick M. Forde, Janice M. Mehnert, Deborah Collyar, Marcus O. Butler, Erica L. Dixon, Laura Q.M. Chow

    出版 2017
    獲取全文
    Editorial
    加到收藏夾
    Saved in:
  4. 4
    Ethics of Mandatory Research Biopsy for Correlative End Points Within Clinical Trials in Oncology

    Ethics of Mandatory Research Biopsy for Correlative End Points Within Clinical Trials in Oncology 由 Jeffrey Peppercorn, Iuliana Shapira, Deborah Collyar, Teresa L. Deshields, Nancy U. Lin, Ian E. Krop, Hans Grünwald, Paula N. Friedman, Ann H. Partridge, Richard L. Schilsky, Monica M. Bertagnolli

    出版 2010
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision

    Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision 由 Leisha A. Emens, Pedro Romero, Ana C. Anderson, Tullia C. Bruno, Christian M. Capitini, Deborah Collyar, James L. Gulley, Patrick Hwu, Avery D. Posey, Ann W. Silk, Jennifer A. Wargo

    出版 2024
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  6. 6
    The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS)

    The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS) 由 E. Shelley Hwang, Terry Hyslop, Thomas Lynch, Elizabeth S. Frank, Donna Pinto, Desiree Basila, Deborah Collyar, Antonia V. Bennett, Celia P. Kaplan, Shoshana M. Rosenberg, Alastair M. Thompson, Anna Weiss, Ann H. Partridge

    出版 2019
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    Community Needs, Concerns, and Perceptions About Health Research: Findings From the Clinical and Translational Science Award Sentinel Network

    Community Needs, Concerns, and Perceptions About Health Research: Findings From the Clinical and Translational Science Award Sentinel Network 由 Linda B. Cottler, Donna Jo McCloskey, Sergio Aguilar‐Gaxiola, Nancy M. Bennett, Hal Strelnick, Molly Dwyer‐White, Deborah Collyar, Shaun Ajinkya, Sarena D. Seifer, Catina O’Leary, Catherine W. Striley, Bradley Evanoff

    出版 2013
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update

    Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideli... 由 Ian E. Krop, Nofisat Ismaila, Fabrice André, Robert C. Bast, William E. Barlow, Deborah Collyar, M. Elizabeth Hammond, Nicole M. Kuderer, Minetta C. Liu, Robert Mennel, Catherine Van Poznak, Antonio C. Wolff, Vered Stearns

    出版 2017
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update—Integration of Results From TAILORx

    Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update—Integration of Results... 由 Fabrice André, Nofisat Ismaila, N. Lynn Henry, Mark R. Somerfield, Robert C. Bast, William E. Barlow, Deborah Collyar, M. Elizabeth Hammond, Nicole M. Kuderer, Minetta C. Liu, Catherine Van Poznak, Antonio C. Wolff, Vered Stearns

    出版 2019
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

    Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideli... 由 Lyndsay N. Harris, Nofisat Ismaila, Lisa M. McShane, Fabrice André, Deborah Collyar, Ana M. González-Angulo, Elizabeth H. Hammond, Nicole M. Kuderer, Minetta C. Liu, Robert Mennel, Catherine Van Poznak, Robert C. Bast, Daniel F. Hayes

    出版 2016
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  11. 11
    Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update

    Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update 由 Fabrice André, Nofisat Ismaila, Kimberly H. Allison, William E. Barlow, Deborah Collyar, Senthil Damodaran, N. Lynn Henry, Komal Jhaveri, Kevin Kalinsky, Nicole M. Kuderer, Anya M. Litvak, Erica L. Mayer, Lajos Pusztai, Rachel Raab, Antonio C. Wolff, Vered Stearns

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

    Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Resp... 由 William M. Sikov, Donald A. Berry, Charles M. Perou, Baljit Singh, Constance Cirrincione, Sara M. Tolaney, Charles Kuzma, Timothy Pluard, George Somlo, Elisa Port, Mehra Golshan, Jennifer R. Bellon, Deborah Collyar, Olwen Hahn, Lisa A. Carey, Clifford A. Hudis, Eric P. Winer

    出版 2014
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction

    American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Bre... 由 Kala Visvanathan, Rowan T. Chlebowski, Patricia A. Hurley, Nananda F. Col, Mary E. Ropka, Deborah Collyar, Monica Morrow, Carolyn D. Runowicz, Kathleen I. Pritchard, Karen L. Hagerty, Banu K. Arun, Judy E. Garber, Victor G. Vogel, James L. Wade, Powel H. Brown, Jack Cuzick, Barnett S. Kramer, Scott M. Lippman

    出版 2009
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study

    Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study 由 Renée Schmitz, Alexandra W. van den Belt‐Dusebout, Karen Clements, Yi Ren, Chiara Cresta, Jasmine Timbres, Yat-Hee Liu, Danalyn Byng, Thomas R. Lynch, Brian A. Menegaz, Deborah Collyar, Terry Hyslop, Samantha M. Thomas, Jason K. Love, Michael Schaapveld, Proteeti Bhattacharjee, Marc D. Ryser, Elinor J. Sawyer, E. Shelley Hwang, Alastair M. Thompson, Jelle Wesseling, Esther H. Lips, Marjanka K. Schmidt

    出版 2023
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer

    CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Nega... 由 Jonathan H. Shepherd, Karla V. Ballman, Mei‐Yin C. Polley, Jordan D. Campbell, Huihui Fan, Sara R. Selitsky, Aranzazu Fernández-Martínez, Joel S. Parker, Katherine A. Hoadley, Zhiyuan Hu, Yan Li, Matthew G. Soloway, Patricia A. Spears, Baljit Singh, Sara M. Tolaney, George Somlo, Elisa R. Port, X. Cynthia, Charles Kuzma, Eleftherios P. Mamounas, Mehra Golshan, Jennifer R. Bellon, Deborah Collyar, Olwen Hahn, Clifford A. Hudis, Eric P. Winer, Ann H. Partridge, Terry Hyslop, Lisa A. Carey, Charles M. Perou, William M. Sikov

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols

    Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols 由 Tricia R. Cottrell, Michael T. Lotze, Alaa M. Ali, Carlo Bifulco, Christian M. Capitini, Laura Q.M. Chow, Anthony R. Cillo, Deborah Collyar, Leslie Cope, Julie S. Deutsch, Genia Dubrovsky, Sacha Gnjatic, Denise Goh, Susan Halabi, Gary Kohanbash, Holden T. Maecker, Saman Maleki Vareki, Sarah Mullin, Barbara Seliger, Janis M. Taube, Wim Vos, Joe Yeong, Kristin G. Anderson, Tullia C. Bruno, Codruța Chiuzan, Iván Díaz-Padilla, Elizabeth Garrett‐Mayer, Isabella C. Glitza Oliva, Paola Grandi, Elizabeth G. Hill, Brian P. Hobbs, Yana G. Najjar, Phyllis Pettit Nassi, Virgil Simons, Sumit K. Subudhi, Ryan J. Sullivan, Chris H. Takimoto

    出版 2025
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer

    Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer 由 Esther H. Lips, Tapsi Kumar, Anargyros Megalios, Lindy L. Visser, Michael Sheinman, Angelo Fortunato, Vandna Shah, Marlous Hoogstraat, Emi Sei, Diego Mallo, Maria Roman-Escorza, Ahmed A. Ahmed, Mingchu Xu, Alexandra W. van den Belt‐Dusebout, Wim Brugman, Tod D. Casasent, Karen Clements, Helen Davies, Liping Fu, Anita Grigoriadis, Timothy Hardman, Lorraine King, Marielle Krete, Petra Kristel, Michiel de Maaker, Carlo C. Maley, Jeffrey R. Marks, Brian A. Menegaz, Lennart Mulder, Frank Nieboer, Salpie Nowinski, Sarah E. Pinder, Jelmar Quist, Carolina Salinas-Souza, Michael Schaapveld, Marjanka K. Schmidt, Abeer M. Shaaban, Rana Shami, Mathini Sridharan, John H. Zhang, Hilary Stobart, Deborah Collyar, Serena Nik‐Zainal, Lodewyk F.A. Wessels, E. Shelley Hwang, Nicholas E. Navin, P. Andrew Futreal, P. Andrew Futreal, E. Shelley Hwang, Jos Jonkers, Jacco, Fariba Behbod, Daniel Rea, Proteeti Bhattacharjee, Donna Pinto, Ellen Verschuur, Marja van Oirsouw, Alastair M. Thompson, Jelle Wesseling, Elinor J. Sawyer

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: